FineMark National Bank & Trust - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 177 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2015. The put-call ratio across all filers is 1.16 and the average weighting 0.1%.

Quarter-by-quarter ownership
FineMark National Bank & Trust ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q4 2015$1,0000.0%40.0%0.00%
Q3 2015$1,0000.0%40.0%0.00%
Q2 2015$1,0000.0%40.0%0.00%
Q1 2015$1,0000.0%4
-42.9%
0.00%
Q4 2014$1,0000.0%7
+133.3%
0.00%
Q3 2014$1,0000.0%30.0%0.00%
Q2 2014$1,0000.0%30.0%0.00%
Q1 2014$1,000
-50.0%
3
-81.2%
0.00%
Q4 2013$2,000160.00%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q3 2015
NameSharesValueWeighting ↓
Samsara BioCapital, LLC 640,688$14,787,0002.73%
DeepCurrents Investment Group LLC 416,800$9,620,0000.33%
DUALITY ADVISERS, LP 105,668$2,439,0000.21%
EULAV Asset Management 335,000$7,732,0000.21%
Virtus ETF Advisers LLC 19,375$447,0000.19%
Hennion & Walsh Asset Management, Inc. 135,214$3,121,0000.19%
PDT Partners, LLC 110,592$2,552,0000.18%
KETTLE HILL CAPITAL MANAGEMENT, LLC 70,256$1,622,0000.16%
ALTRINSIC GLOBAL ADVISORS LLC 168,800$3,896,0000.12%
WOODWARD DIVERSIFIED CAPITAL, LLC 8,939$206,0000.12%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders